173 related articles for article (PubMed ID: 10861090)
1. Mechanism of paclitaxel activity in Kaposi's sarcoma.
Sgadari C; Toschi E; Palladino C; Barillari G; Carlei D; Cereseto A; Ciccolella C; Yarchoan R; Monini P; Stürzl M; Ensoli B
J Immunol; 2000 Jul; 165(1):509-17. PubMed ID: 10861090
[TBL] [Abstract][Full Text] [Related]
2. Immunihistochemical detection of Bcl-2 in AIDS-associated and classical Kaposi's sarcoma.
Morris CB; Gendelman R; Marrogi AJ; Lu M; Lockyer JM; Alperin-Lea W; Ensoli B
Am J Pathol; 1996 Apr; 148(4):1055-63. PubMed ID: 8644847
[TBL] [Abstract][Full Text] [Related]
3. Inflammatory cytokines induce AIDS-Kaposi's sarcoma-derived spindle cells to produce and release basic fibroblast growth factor and enhance Kaposi's sarcoma-like lesion formation in nude mice.
Samaniego F; Markham PD; Gallo RC; Ensoli B
J Immunol; 1995 Apr; 154(7):3582-92. PubMed ID: 7897237
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of Bcl-2 in Kaposi's sarcoma-derived cells.
Simonart T; Degraef C; Noel JC; Fokan D; Zhou L; Pradier O; Ducarme M; Schandene L; Van Vooren JP; Parent D; Heenen M
J Invest Dermatol; 1998 Sep; 111(3):349-53. PubMed ID: 9740222
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development.
Samaniego F; Markham PD; Gendelman R; Watanabe Y; Kao V; Kowalski K; Sonnabend JA; Pintus A; Gallo RC; Ensoli B
Am J Pathol; 1998 Jun; 152(6):1433-43. PubMed ID: 9626048
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Kaposi's sarcoma in vivo by fenretinide.
Ferrari N; Morini M; Pfeffer U; Minghelli S; Noonan DM; Albini A
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):6020-9. PubMed ID: 14676128
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms in the pathogenesis of AIDS-associated Kaposi's sarcoma.
Ensoli B; Barillari G; Buonaguro L; Gallo RC
Adv Exp Med Biol; 1991; 303():27-38. PubMed ID: 1805571
[TBL] [Abstract][Full Text] [Related]
8. Histological characterization of regression in acquired immunodeficiency syndrome-related Kaposi's sarcoma.
Pantanowitz L; Dezube BJ; Pinkus GS; Tahan SR
J Cutan Pathol; 2004 Jan; 31(1):26-34. PubMed ID: 14675282
[TBL] [Abstract][Full Text] [Related]
9. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma.
Sgadari C; Barillari G; Toschi E; Carlei D; Bacigalupo I; Baccarini S; Palladino C; Leone P; Bugarini R; Malavasi L; Cafaro A; Falchi M; Valdembri D; Rezza G; Bussolino F; Monini P; Ensoli B
Nat Med; 2002 Mar; 8(3):225-32. PubMed ID: 11875492
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-1 beta increases the BCL-2/BAX ratio in Kaposi's sarcoma cells.
Simonart T; Van Vooren JP
Cytokine; 2002 Sep; 19(6):259-66. PubMed ID: 12421568
[TBL] [Abstract][Full Text] [Related]
11. Thrombospondin-1 inhibits Kaposi's sarcoma (KS) cell and HIV-1 Tat-induced angiogenesis and is poorly expressed in KS lesions.
Taraboletti G; Benelli R; Borsotti P; Rusnati M; Presta M; Giavazzi R; Ruco L; Albini A
J Pathol; 1999 May; 188(1):76-81. PubMed ID: 10398144
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of basic fibroblast growth factor and the alpha v beta 3 integrin.
Barillari G; Sgadari C; Palladino C; Gendelman R; Caputo A; Morris CB; Nair BC; Markham P; Nel A; Stürzl M; Ensoli B
J Immunol; 1999 Aug; 163(4):1929-35. PubMed ID: 10438928
[TBL] [Abstract][Full Text] [Related]
13. AIDS-related Kaposi's sarcoma cells rapidly internalize endostatin, which co-localizes to tropomysin microfilaments and inhibits cytokine-mediated migration and invasion.
Mallery SR; Morse MA; Wilson RF; Pei P; Ness GM; Bradburn JE; Renner RJ; Schuller DE; Robertson FM
J Cell Biochem; 2003 May; 89(1):133-43. PubMed ID: 12682914
[TBL] [Abstract][Full Text] [Related]
14. Expression of the fibroblast/macrophage marker 1B10 by spindle cells in Kaposi's sarcoma lesions and by Kaposi's sarcoma-derived tumor cells.
Simonart T; Degraef C; Heenen M; Hermans P; Van Vooren JP; Noel JC
J Cutan Pathol; 2002 Feb; 29(2):72-8. PubMed ID: 12150136
[TBL] [Abstract][Full Text] [Related]
15. Consensus-interferon and platelet-derived growth factor adversely regulate proliferation and migration of Kaposi's sarcoma cells by control of c-myc expression.
Köster R; Blatt LM; Streubert M; Zietz C; Hermeking H; Brysch W; Stürzl M
Am J Pathol; 1996 Dec; 149(6):1871-85. PubMed ID: 8952524
[TBL] [Abstract][Full Text] [Related]
16. HIV type 1 Tat protein is a survival factor for Kaposi's sarcoma and endothelial cells.
Cantaluppi V; Biancone L; Boccellino M; Doublier S; Benelli R; Carlone S; Albini A; Camussi G
AIDS Res Hum Retroviruses; 2001 Jul; 17(10):965-76. PubMed ID: 11461682
[TBL] [Abstract][Full Text] [Related]
17. Induction of programmed cell death in Kaposi's sarcoma cells by preparations of human chorionic gonadotropin.
Samaniego F; Bryant JL; Liu N; Karp JE; Sabichi AL; Thierry A; Lunardi-Iskandar Y; Gallo RC
J Natl Cancer Inst; 1999 Jan; 91(2):135-43. PubMed ID: 9923854
[TBL] [Abstract][Full Text] [Related]
18. Treatment of advanced classic Kaposi's sarcoma with weekly low-dose paclitaxel therapy.
Baskan EB; Tunali S; Adim SB; Kiyici M; Ali R
Int J Dermatol; 2006 Dec; 45(12):1441-3. PubMed ID: 17184252
[No Abstract] [Full Text] [Related]
19. Kaposi's sarcoma pathogenesis: a link between immunology and tumor biology.
Ensoli B; Sirianni MC
Crit Rev Oncog; 1998; 9(2):107-24. PubMed ID: 9973245
[TBL] [Abstract][Full Text] [Related]
20. Angiogenic potential in vivo by Kaposi's sarcoma cell-free supernatants and HIV-1 tat product: inhibition of KS-like lesions by tissue inhibitor of metalloproteinase-2.
Albini A; Fontanini G; Masiello L; Tacchetti C; Bigini D; Luzzi P; Noonan DM; Stetler-Stevenson WG
AIDS; 1994 Sep; 8(9):1237-44. PubMed ID: 7528513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
